oncology is a very tough segment for pharma and biotech. below $6.9 is not much of a risky buy, but when it hits $16.9 i may look deeper into it. for now, too much half starts and half stops with its execution.
oncology is a very tough segment for pharma and biotech. below $6.9 is not much of a risky buy, but when it hits $16.9 i may look deeper into it. for now, too much half starts and half stops with its execution.